Value-based pricing

Sanofi Blinks First: Zaltrap Price Cut Proves HTA Has Reached The US

Posted by on Nov 12, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payers: Managed Medicaid/Medicare, Payment Reform, Pharmaceuticals, Pricing, Product Launch, Value-based pricing

Sanofi’s decision last week to cut the price of its colon cancer drug Zaltrap by up to 50% showed that the US market is no longer immune to European-style drug price pressure. Never mind that the move...

Learn More

The Value Debate: Can Personalized Drugs Support Personalized Pricing?

Posted by on Oct 10, 2012 in Adherence, Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payers: Commercial, Payment Reform, Personalized Medicine, Pharmaceuticals, Pricing, Value-based pricing

“Personalized health care requires a new reimbursement model,” declared Roche’s VP Global Pricing & Market Access Jens Grueger in the elegant London county hall debating chamber on...

Learn More

Risk-Shares Pop Up Again As Payers, Pharma Circle New Payment Models

Posted by on Oct 3, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payer Management Tool, Payers: Commercial, Payment Reform, Pharmaceuticals, Physician practice patterns, Pricing, Product Launch, Value-based pricing

Say you’re GSK, and a head-to-head trial pitting your drug against the market leader showed non-inferiority. Say, too, that even though you assembled some trial evidence that patients preferred your drug vs....

Learn More

Patient-Based Pricing: An Answer To The Soaring Cost of Innovation?

Posted by on Sep 21, 2012 in Company, Cost/Comparative Effectiveness, Health Technology Assessments, Medical Innovation, Payers: Commercial, Payment Reform, Personalized Medicine, Pharmaceuticals, Pricing, Uncategorized, Value-based pricing

Roche’s investor day on Sept. 5 provided heartening news for breast cancer patients. Executives outlined an array of increasingly targeted therapeutic permutations to combat the tumor, building on its...

Learn More